STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
Phase: III
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001) Read Moreabout Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
Phase: III
STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor-Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001) Read Moreabout STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)
Phase: III
Ph3 HER2/neu BC (FLAMINGO-01)
A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)
Phase: III
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase: III
Ph3 study of standard endocrine therapy with breast cancer
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer
Phase: III
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
Phase: III
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
STAR Ph3 study to evaluate to treat patients with HNSCC
A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC
Phase: III
Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001 Read Moreabout Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
Phase: I/II
Ph2/3 study to evaluate the safety of telisotuzumab in combo with NSCL
A Phase 2/3 Randomized Study to Evaluate the Safety Efficacy and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Read Moreabout Ph2/3 study to evaluate the safety of telisotuzumab in combo with NSCL
Phase: II/III
Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
Phase: II
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
Phase: IIIB
Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001) Read Moreabout Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC
Phase: III
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304) Read Moreabout Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
Phase: III
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303) Read Moreabout Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
Phase: III
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph1/2 FIH MRTX1719 ST MTAP Deletion
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007) Read Moreabout Ph1/2 FIH MRTX1719 ST MTAP Deletion
Phase: I/II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001) Read Moreabout Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
Phase: I/II